BioCentury
ARTICLE | Company News

New dose regimen for Alkermes' aripiprazole approved

July 2, 2018 7:21 PM UTC

Alkermes plc (NASDAQ:ALKS) said FDA approved Aristada Initio aripiprazole lauroxil in combination with oral aripiprazole for adult schizophrenia patients initiating treatment with Aristada.

Aristada previously required three weeks of oral aripiprazole supplementation following the first injection. Aristada Initio does not require supplementation and allows patients to receive a single oral aripiprazole dose in combination with the first dose of Aristada Initio in one day...